Go Pro
→ Urgent exposé on the 'Mar-a-Lago Trade' (From Stansberry Research) (Ad)tc pixel Free UTMD Stock Alerts

Utah Medical Products (UTMD) Financials

Utah Medical Products logo
$72.78 0.00 (0.00%)
Closing price 07/2/2026 04:00 PM Eastern
Extended Trading
$72.99 +0.21 (+0.29%)
As of 07/2/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Utah Medical Products

Annual Income Statements for Utah Medical Products

This table shows Utah Medical Products' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 9.12 5.84 12 16 16 12 14 13 18 13 14
Consolidated Net Income / (Loss)		 12 12 8.51 19 15 11 15 16 17 14 11
Net Income / (Loss) Continuing Operations		 12 12 8.51 19 15 11 15 16 17 14 11
Total Pre-Tax Income 		16 16 19 19 18 14 19 21 20 17 14
Total Operating Income		 16 16 19 19 18 14 19 20 17 14 11
Total Gross Profit		 24 24 26 26 29 26 31 32 30 24 22
Total Revenue		 40 39 41 42 47 42 49 52 50 41 39
Operating Revenue		 40 39 41 42 47 42 49 52 50 41 39
Total Cost of Revenue		 16 16 15 16 17 17 18 20 20 17 17
Operating Cost of Revenue		 16 16 15 16 17 17 18 20 20 17 17
Total Operating Expenses		 8.53 7.50 7.38 7.61 12 12 12 12 13 11 11
Selling, General & Admin Expense		 5.85 5.36 5.39 5.45 9.61 9.80 10 10 11 7.84 7.88
Marketing Expense		 2.16 1.67 1.54 1.71 1.74 1.55 1.41 1.51 1.69 1.90 2.05
Research & Development Expense		 0.52 0.48 0.45 0.45 0.48 0.49 0.53 0.49 0.56 0.81 0.67
Total Other Income / (Expense), net		 -0.11 0.24 0.07 0.76 0.25 0.13 0.18 0.87 3.31 3.21 2.71
Interest & Investment Income		 0.10 0.10 0.10 0.33 0.26 0.13 0.18 0.68 3.06 3.38 2.83
Other Income / (Expense), net		 -0.14 0.13 -0.03 0.44 -0.01 0.00 0.00 0.19 0.26 -0.17 -0.12
Income Tax Expense		 3.70 4.29 11 0.90 3.16 3.04 4.27 4.19 3.45 2.93 2.82
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 2.73 6.28 -3.90 2.95 -1.51 -1.50 0.77 2.99 -1.38 1.25 -2.49
Basic Earnings per Share		 $3.16 $3.23 $2.29 $4.97 $3.96 $2.95 $4.05 $4.53 $4.58 $3.96 $3.48
Weighted Average Basic Shares Outstanding		 2.90M 1.80M 5.40M 3.72M 3.70M 3.65M 3.65M 3.63M 3.59M 3.28M 3.19M
Diluted Earnings per Share		 $3.14 $3.22 $2.28 $4.95 $3.94 $2.94 $4.04 $4.52 $4.57 $3.96 $3.48
Weighted Average Diluted Shares Outstanding		 2.90M 1.80M 5.40M 3.72M 3.70M 3.65M 3.65M 3.63M 3.59M 3.28M 3.19M
Weighted Average Basic & Diluted Shares Outstanding		 2.90M 1.80M 5.40M 3.72M 3.70M 3.65M 3.65M 3.63M 3.59M 3.28M 3.19M

Quarterly Income Statements for Utah Medical Products

This table shows Utah Medical Products' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 2.92 5.63 3.33 3.42 5.00 0.89 3.76 4.88 2.10
Consolidated Net Income / (Loss)		 3.94 4.29 3.96 3.45 3.56 2.90 3.04 3.05 2.60
Net Income / (Loss) Continuing Operations		 3.94 4.29 3.96 3.45 3.56 2.90 3.04 3.05 2.60
Total Pre-Tax Income 		4.78 5.02 4.80 4.21 4.18 3.61 3.86 3.84 3.18
Total Operating Income		 3.97 3.94 3.88 3.44 3.34 2.93 3.15 3.20 2.57
Total Gross Profit		 7.36 7.10 6.77 6.25 5.80 5.32 5.54 5.60 5.28
Total Revenue		 13 12 11 10 10 9.16 9.71 9.95 8.72
Operating Revenue		 13 12 11 10 10 9.16 9.71 9.95 8.72
Total Cost of Revenue		 5.15 5.24 4.57 4.15 4.20 3.84 4.17 4.36 3.44
Operating Cost of Revenue		 5.15 5.24 4.57 4.15 4.20 3.84 4.17 4.36 3.44
Total Operating Expenses		 3.39 3.15 2.88 2.82 2.46 2.39 2.39 2.40 2.72
Selling, General & Admin Expense		 3.25 1.32 2.62 2.56 2.29 0.37 2.23 2.26 2.56
Research & Development Expense		 0.14 0.15 0.27 0.26 0.17 0.12 0.15 0.14 0.15
Total Other Income / (Expense), net		 0.81 1.07 0.92 0.77 0.84 0.68 0.71 0.64 0.62
Other Income / (Expense), net		 0.81 -1.98 0.92 0.77 0.84 -2.70 0.71 0.64 0.62
Income Tax Expense		 0.85 0.73 0.84 0.76 0.62 0.71 0.82 0.79 0.58
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 1.01 -1.34 0.63 0.03 -1.43 2.02 -0.72 -1.83 0.50
Basic Earnings per Share		 $1.08 $1.18 $1.09 $0.98 $1.02 $0.87 $0.92 $0.94 $0.82
Weighted Average Basic Shares Outstanding		 3.63M 3.59M 3.62M 3.53M 3.48M 3.28M 3.31M 3.25M 3.19M
Diluted Earnings per Share		 $1.08 $1.18 $1.09 $0.98 $1.02 $0.87 $0.92 $0.94 $0.82
Weighted Average Diluted Shares Outstanding		 3.64M 3.59M 3.62M 3.53M 3.48M 3.28M 3.31M 3.25M 3.19M
Weighted Average Basic & Diluted Shares Outstanding		 3.63M 3.59M 3.53M 3.48M 3.39M 3.28M 3.25M 3.21M 3.18M

Annual Cash Flow Statements for Utah Medical Products

This table details how cash moves in and out of Utah Medical Products' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 4.00 3.02 14 11 -8.33 8.80 9.38 14 18 -9.89 3.30
Net Cash From Operating Activities		 14 15 17 17 17 20 21 21 22 15 15
Net Cash From Continuing Operating Activities		 14 13 17 17 17 20 21 21 23 15 16
Net Income / (Loss) Continuing Operations		 12 12 8.51 19 15 11 15 16 17 14 11
Consolidated Net Income / (Loss)		 12 12 8.51 19 15 11 15 16 17 14 11
Depreciation Expense		 0.62 0.61 0.66 0.77 0.70 0.66 0.64 0.61 0.62 0.73 0.83
Amortization Expense		 2.53 2.22 2.11 2.19 6.18 6.55 6.65 6.47 5.75 2.12 2.18
Non-Cash Adjustments To Reconcile Net Income		 0.08 0.10 5.94 -3.04 -0.16 0.16 0.19 0.21 0.19 0.25 0.74
Changes in Operating Assets and Liabilities, net		 -1.27 -0.53 -0.31 -1.64 -4.39 1.97 -1.06 -2.62 -0.22 -1.78 0.98
Net Cash From Investing Activities		 -0.25 -3.30 -1.60 0.53 -22 -0.86 -0.55 -0.82 -0.64 -0.21 -0.37
Net Cash From Continuing Investing Activities		 -0.25 -3.30 -1.60 0.53 -22 -0.86 -0.55 -0.82 -0.64 -0.21 -0.37
Purchase of Property, Plant & Equipment		 -0.18 -3.29 -1.60 -0.40 -0.54 -0.86 -0.55 -0.81 -0.64 -0.23 -0.37
Acquisitions		 -0.07 -0.01 0.00 0.00 -21 0.00 0.00 -0.01 0.00 -0.01 0.00
Sale of Property, Plant & Equipment		 - 0.00 0.00 0.86 - - - 0.00 0.00 0.03 0.00
Net Cash From Financing Activities		 -8.89 -6.34 -2.65 -4.78 -4.23 -11 -11 -5.48 -4.17 -24 -12
Net Cash From Continuing Financing Activities		 -8.89 -6.34 -2.65 -4.78 -4.23 -11 -11 -5.48 -4.17 -24 -12
Repurchase of Common Equity		 - - 0.00 -1.21 -0.40 -6.98 0.00 -2.50 0.00 -20 -8.36
Payment of Dividends		 -3.85 -3.92 -2.96 -4.03 -4.11 -4.12 -11 -3.16 -4.28 -4.26 -3.98
Issuance of Common Equity		 0.34 0.38 0.30 0.45 0.28 0.36 0.56 0.17 0.12 0.39 0.00
Cash Interest Paid		 0.07 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Income Taxes Paid		 5.34 4.85 5.15 4.85 5.30 3.19 4.62 4.97 4.83 4.64 4.00

Quarterly Cash Flow Statements for Utah Medical Products

This table details how cash moves in and out of Utah Medical Products' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
Net Change in Cash & Equivalents		 3.59 4.66 0.94 -4.59 -0.77 -5.48 0.35 -1.15 1.65
Net Cash From Operating Activities		 5.12 5.33 5.28 2.76 3.86 2.94 4.46 2.87 3.11
Net Cash From Continuing Operating Activities		 5.12 6.03 5.28 2.76 3.86 2.94 4.46 2.87 3.11
Net Income / (Loss) Continuing Operations		 3.94 4.29 3.96 3.45 3.56 2.90 3.04 3.05 2.60
Consolidated Net Income / (Loss)		 3.94 4.29 3.96 3.45 3.56 2.90 3.04 3.05 2.60
Depreciation Expense		 0.16 0.16 0.16 0.17 0.20 0.20 0.20 0.21 0.21
Amortization Expense		 1.63 0.88 0.53 0.52 0.54 0.53 0.52 0.55 0.48
Non-Cash Adjustments To Reconcile Net Income		 0.05 0.07 0.07 0.05 0.05 0.07 0.07 0.09 0.12
Changes in Operating Assets and Liabilities, net		 -0.65 0.63 0.57 -1.44 -0.50 -0.77 0.63 -1.02 -0.30
Net Cash From Investing Activities		 -0.19 -0.09 0.01 -0.12 -0.09 -0.01 -0.18 -0.05 -0.13
Net Cash From Continuing Investing Activities		 -0.19 -0.09 0.01 -0.12 -0.09 -0.01 -0.18 -0.05 -0.13
Purchase of Property, Plant & Equipment		 -0.19 -0.09 -0.02 -0.11 -0.09 -0.01 -0.18 -0.05 -0.13
Net Cash From Financing Activities		 -1.04 -1.07 -3.98 -7.19 -4.92 -7.75 -4.24 -4.49 -1.12
Net Cash From Continuing Financing Activities		 -1.04 -1.07 -3.98 -7.19 -4.92 -7.75 -4.24 -4.49 -1.12
Repurchase of Common Equity		 - - -2.99 -6.40 -3.87 -6.71 -3.22 -3.49 -0.13
Payment of Dividends		 -1.07 -1.07 -1.09 -1.08 -1.05 -1.04 -1.02 -1.00 -0.99
Other Net Changes in Cash		 - - - - - - - - -0.21
Cash Interest Paid		 - - 0.00 - - - 0.00 - 0.00
Cash Income Taxes Paid		 0.94 1.34 0.11 2.69 0.92 0.93 0.05 2.28 0.03

Annual Balance Sheets for Utah Medical Products

This table presents Utah Medical Products' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 79 76 93 100 110 112 116 124 135 123 123
Total Current Assets		 33 34 49 61 55 62 73 90 106 96 98
Cash & Equivalents		 23 26 40 51 43 52 61 75 93 83 86
Accounts Receivable		 4.56 3.21 3.62 3.96 4.74 4.10 5.13 5.54 3.39 4.09 3.52
Inventories, net		 4.20 4.54 5.24 5.41 6.91 6.22 6.60 8.81 9.58 8.81 7.94
Other Current Assets		 0.42 0.36 0.37 0.42 0.44 0.35 0.46 0.52 0.43 0.45 0.53
Plant, Property, & Equipment, net		 7.37 9.97 12 10 11 11 11 10 11 9.76 9.91
Total Noncurrent Assets		 39 32 32 29 44 38 32 24 19 16 15
Goodwill		 15 13 14 14 14 14 14 13 14 14 14
Intangible Assets		 24 18 18 15 30 24 18 10 4.95 2.87 0.84
Total Liabilities & Shareholders' Equity		 79 76 93 100 110 112 116 124 135 123 123
Total Liabilities		 9.53 6.95 15 11 8.69 8.92 8.50 9.62 7.15 5.11 3.27
Total Current Liabilities		 4.07 3.02 5.28 5.26 3.45 3.79 3.75 5.96 4.71 3.76 2.60
Accounts Payable		 0.65 0.91 0.93 0.98 1.10 0.79 0.76 1.22 0.77 0.70 0.91
Accrued Expenses		 3.42 2.12 4.35 4.29 2.35 3.00 2.98 4.74 3.94 3.06 1.69
Total Noncurrent Liabilities		 5.46 3.93 9.34 5.52 5.25 5.13 4.75 3.66 2.44 1.35 0.68
Long-Term Debt		 - - - - - - - - 0.30 0.28 0.23
Noncurrent Deferred & Payable Income Tax Liabilities		 5.46 3.93 9.34 5.52 4.87 4.80 4.36 3.32 1.44 1.07 0.45
Total Equity & Noncontrolling Interests		 70 69 78 89 101 103 107 114 128 117 119
Total Preferred & Common Equity		 70 69 78 89 101 103 107 114 128 117 119
Total Common Equity		 70 69 78 89 101 103 107 114 128 117 119
Common Stock		 2.75 0.42 0.85 0.16 0.06 0.15 0.88 0.29 0.63 0.03 0.03
Retained Earnings		 73 81 86 100 111 111 115 126 138 129 129
Accumulated Other Comprehensive Income / (Loss)		 -5.96 -12 -8.34 -11 - -8.28 -9.05 -12 -11 - -9.42

Quarterly Balance Sheets for Utah Medical Products

This table presents Utah Medical Products' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 3/31/2026
Total Assets		 131 135 130 130 123 121 124
Total Current Assets		 102 107 102 102 96 94 100
Cash & Equivalents		 88 94 89 88 83 82 87
Accounts Receivable		 3.49 3.59 3.67 3.72 3.94 3.63 3.64
Inventories, net		 9.71 9.24 9.06 9.11 8.65 8.23 8.72
Other Current Assets		 0.44 0.51 0.38 0.38 0.48 0.33 0.61
Plant, Property, & Equipment, net		 10 10 10 10 9.95 10 9.72
Total Noncurrent Assets		 19 18 18 18 16 16 14
Goodwill		 13 14 14 14 14 14 14
Intangible Assets		 5.63 4.39 3.88 3.59 2.41 1.98 0.36
Total Liabilities & Shareholders' Equity		 131 135 130 130 123 121 124
Total Liabilities		 7.54 7.70 5.98 5.50 5.47 3.27 4.01
Total Current Liabilities		 4.18 5.47 3.94 3.44 4.32 2.25 3.51
Accounts Payable		 0.51 1.00 0.83 1.00 0.91 0.74 1.19
Accrued Expenses		 3.67 4.48 3.11 2.44 3.41 1.52 2.31
Total Noncurrent Liabilities		 3.36 2.23 2.04 2.06 1.15 1.02 0.50
Long-Term Debt		 - - - - 0.27 0.00 0.21
Noncurrent Deferred & Payable Income Tax Liabilities		 1.80 1.24 1.07 1.07 0.88 0.76 0.29
Total Equity & Noncontrolling Interests		 124 128 124 124 117 118 120
Total Preferred & Common Equity		 124 128 124 124 117 118 120
Total Common Equity		 124 128 124 124 117 118 120
Common Stock		 0.56 0.04 0.04 0.03 0.03 0.03 0.03
Retained Earnings		 135 139 135 134 128 127 130
Accumulated Other Comprehensive Income / (Loss)		 -12 -11 -11 -9.89 -11 -9.36 -9.92

Annual Metrics And Ratios for Utah Medical Products

This table displays calculated financial ratios and metrics derived from Utah Medical Products' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 3,750,300.00 3,761,300.00 3,720,600.00 3,734,200.00 3,721,125.00 7,280,806.00 3,650,929.00 3,627,583.00 3,629,525.00 - 3,205,723.00
DEI Adjusted Shares Outstanding		 3,750,300.00 3,761,300.00 3,720,600.00 3,734,200.00 3,721,125.00 7,280,806.00 3,650,929.00 3,627,583.00 3,629,525.00 - 3,205,723.00
DEI Earnings Per Adjusted Shares Outstanding		 2.43 1.55 3.33 4.18 4.36 1.69 3.84 3.72 4.96 - 4.30
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.72% -2.14% 5.38% 1.41% 11.68% -10.08% 16.30% 6.58% -3.93% -18.56% -5.83%
EBITDA Growth		 -3.58% 2.64% 13.58% 1.55% 10.94% -14.65% 25.08% 3.42% -13.52% -30.49% -12.15%
EBIT Growth		 -3.02% 5.20% 16.30% 0.82% -7.89% -22.22% 37.73% 5.82% -14.74% -21.21% -15.93%
NOPAT Growth		 2.27% 0.26% -29.12% 110.41% -18.56% -26.34% 36.96% 7.73% -11.96% -19.20% -18.75%
Net Income Growth		 4.09% 2.41% -29.87% 118.17% -20.63% -26.68% 36.95% 11.39% 0.98% -16.60% -18.65%
EPS Growth		 3.97% 2.55% -29.19% 117.11% -20.40% -25.38% 37.42% 11.88% 1.11% -13.35% -12.12%
Operating Cash Flow Growth		 -10.31% 5.27% 16.38% -0.44% 1.32% 18.06% 5.29% -0.26% 5.36% -33.44% -0.94%
Free Cash Flow Firm Growth		 -6.63% -2.00% -14.27% 37.34% -132.60% 395.17% 15.01% 11.72% -21.01% -30.87% -17.30%
Invested Capital Growth		 -7.54% -7.41% -11.00% -0.75% 53.92% -11.56% -10.48% -14.34% -9.62% -2.82% -2.87%
Revenue Q/Q Growth		 -1.62% -1.82% 3.37% -1.05% 4.63% 0.42% 1.88% 1.28% -2.41% -7.20% 0.00%
EBITDA Q/Q Growth		 -3.24% -1.89% 4.70% -1.72% 6.45% -1.53% 3.19% -0.41% -13.53% -11.14% 0.00%
EBIT Q/Q Growth		 -3.69% -1.49% 5.14% -1.98% 2.24% -2.28% 4.69% -0.45% -14.76% -11.41% 0.00%
NOPAT Q/Q Growth		 1.14% -3.98% -38.03% 45.67% 7.60% -7.76% 4.90% 0.31% -5.15% -8.32% 0.00%
Net Income Q/Q Growth		 1.81% -3.91% -38.12% 46.81% 7.01% -8.06% 5.12% 2.64% -1.60% -9.07% 0.00%
EPS Q/Q Growth		 1.62% -3.59% -38.21% 47.32% 7.07% -7.26% 4.66% 3.20% -1.72% -7.26% 0.00%
Operating Cash Flow Q/Q Growth		 -4.32% -3.46% 7.64% -0.60% 7.28% 0.69% -3.60% 3.39% -1.54% -13.90% 0.00%
Free Cash Flow Firm Q/Q Growth		 -7.77% -14.82% 19.29% 10.18% -18.01% -0.10% -1.84% 0.17% -1.02% 1.96% 0.00%
Invested Capital Q/Q Growth		 -0.78% 4.43% -12.62% -4.05% 0.57% -1.06% 1.11% 1.32% -0.16% -3.64% 0.00%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 60.23% 60.28% 63.73% 62.64% 62.82% 60.57% 63.03% 61.58% 59.81% 59.03% 57.12%
EBITDA Margin		 46.47% 48.74% 52.52% 52.60% 52.25% 49.59% 53.34% 51.76% 46.59% 39.77% 37.10%
Operating Margin		 38.97% 41.19% 45.90% 44.52% 37.59% 32.50% 38.49% 37.85% 33.40% 33.23% 29.60%
EBIT Margin		 38.63% 41.53% 45.83% 45.56% 37.57% 32.50% 38.49% 38.21% 33.91% 32.81% 29.29%
Profit (Net Income) Margin		 29.49% 30.86% 20.54% 44.18% 31.40% 25.60% 30.15% 31.51% 33.12% 33.92% 29.30%
Tax Burden Percent		 76.19% 73.85% 44.57% 95.35% 82.35% 78.02% 77.58% 79.74% 82.81% 82.57% 79.99%
Interest Burden Percent		 100.21% 100.63% 100.54% 101.70% 101.48% 100.96% 100.96% 103.41% 117.94% 125.20% 125.07%
Effective Tax Rate		 23.81% 26.15% 55.43% 4.65% 17.65% 21.98% 22.42% 20.26% 17.19% 17.43% 20.01%
Return on Invested Capital (ROIC)		 24.74% 26.80% 20.91% 46.89% 30.19% 19.47% 29.98% 36.82% 36.91% 31.86% 26.64%
ROIC Less NNEP Spread (ROIC-NNEP)		 25.16% 26.11% 20.81% 45.29% 29.75% 19.25% 29.73% 35.80% 33.63% 28.83% 24.06%
Return on Net Nonoperating Assets (RNNOA)		 -7.09% -9.34% -9.37% -24.68% -14.70% -8.88% -15.89% -21.94% -23.19% -20.56% -17.10%
Return on Equity (ROE)		 17.65% 17.46% 11.54% 22.21% 15.50% 10.59% 14.09% 14.88% 13.72% 11.29% 9.54%
Cash Return on Invested Capital (CROIC)		 32.57% 34.50% 32.55% 47.64% -12.28% 31.73% 41.03% 52.27% 47.01% 34.71% 29.55%
Operating Return on Assets (OROA)		 19.36% 21.01% 22.47% 19.88% 16.82% 12.38% 16.61% 16.68% 13.14% 10.40% 9.21%
Return on Assets (ROA)		 14.78% 15.61% 10.07% 19.28% 14.06% 9.75% 13.01% 13.76% 12.83% 10.76% 9.21%
Return on Common Equity (ROCE)		 17.65% 17.46% 11.54% 22.21% 15.50% 10.59% 14.09% 14.88% 13.72% 11.29% 9.54%
Return on Equity Simple (ROE_SIMPLE)		 17.00% 17.51% 10.89% 20.85% 14.57% 10.50% 13.80% 14.42% 0.00% 11.82% 0.00%
Net Operating Profit after Tax (NOPAT)		 12 12 8.47 18 15 11 15 16 14 11 9.12
NOPAT Margin		 29.69% 30.42% 20.46% 42.45% 30.96% 25.36% 29.86% 30.18% 27.66% 27.44% 23.68%
Net Nonoperating Expense Percent (NNEP)		 -0.43% 0.70% 0.10% 1.60% 0.44% 0.22% 0.25% 1.02% 3.28% 3.02% 2.58%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 13.77% 10.80% 9.54% 7.63%
Cost of Revenue to Revenue		 39.77% 39.72% 36.27% 37.36% 37.18% 39.43% 36.97% 38.42% 40.19% 40.98% 42.88%
SG&A Expenses to Revenue		 14.56% 13.63% 13.02% 12.97% 20.50% 23.23% 20.58% 19.90% 21.93% 19.16% 20.46%
R&D to Revenue		 1.30% 1.21% 1.08% 1.08% 1.03% 1.15% 1.07% 0.94% 1.12% 1.99% 1.73%
Operating Expenses to Revenue		 21.25% 19.09% 17.83% 18.12% 25.23% 28.07% 24.54% 23.73% 26.40% 25.79% 27.52%
Earnings before Interest and Taxes (EBIT)		 16 16 19 19 18 14 19 20 17 13 11
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 19 19 22 22 25 21 26 27 23 16 14
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.77 3.52 3.51 3.19 3.68 2.80 3.29 3.08 2.28 1.77 1.50
Price to Tangible Book Value (P/TBV)		 6.27 6.51 5.94 4.70 6.54 4.46 4.68 3.88 2.67 2.05 1.71
Price to Revenue (P/Rev)		 4.80 6.21 6.62 6.76 7.93 6.83 7.18 6.72 5.82 5.07 4.63
Price to Earnings (P/E)		 21.13 41.75 22.10 18.21 22.93 23.43 25.15 26.07 16.24 16.43 12.96
Dividend Yield		 2.00% 1.61% 1.45% 1.43% 1.10% 1.42% 2.96% 1.20% 1.47% 1.97% 2.20%
Earnings Yield		 4.73% 2.40% 4.53% 5.49% 4.36% 4.27% 3.98% 3.84% 6.16% 6.09% 7.72%
Enterprise Value to Invested Capital (EV/IC)		 3.65 5.08 6.14 6.15 5.65 4.59 6.31 7.00 5.59 3.59 2.76
Enterprise Value to Revenue (EV/Rev)		 4.22 5.54 5.66 5.55 7.02 5.62 5.94 5.30 3.98 3.05 2.41
Enterprise Value to EBITDA (EV/EBITDA)		 9.07 11.36 10.77 10.55 13.44 11.32 11.14 10.23 8.54 7.66 6.51
Enterprise Value to EBIT (EV/EBIT)		 10.91 13.34 12.34 12.18 18.69 17.28 15.44 13.86 11.74 9.29 8.24
Enterprise Value to NOPAT (EV/NOPAT)		 14.20 18.21 27.64 13.07 22.69 22.15 19.90 17.54 14.39 11.11 10.20
Enterprise Value to Operating Cash Flow (EV/OCF)		 12.27 14.98 13.85 13.84 19.31 11.76 13.75 13.09 8.97 8.41 6.33
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.78 14.15 17.76 12.86 0.00 13.59 14.54 12.36 11.30 10.19 9.19
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.28 -0.36 -0.45 -0.54 -0.49 -0.46 -0.53 -0.61 -0.69 -0.71 -0.71
Leverage Ratio		 1.19 1.12 1.15 1.15 1.10 1.09 1.08 1.08 1.07 1.05 1.04
Compound Leverage Factor		 1.20 1.13 1.15 1.17 1.12 1.10 1.09 1.12 1.26 1.31 1.30
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.32% 0.00% 0.30% 0.23% 0.24% 0.19%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.32% 0.00% 0.30% 0.23% 0.24% 0.19%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 99.68% 100.00% 99.70% 99.77% 99.76% 99.81%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.01 0.01 0.02 0.02
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 -2.45 0.00 -2.76 -3.96 -5.08 -5.99
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.02 0.00 0.01 0.01 0.02 0.02
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.02 0.02 0.03 0.02
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 -4.79 0.00 -4.73 -6.66 -7.37 -9.38
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.03 0.00 0.02 0.02 0.03 0.02
Altman Z-Score		 15.01 24.28 14.23 18.95 28.62 22.17 27.96 25.12 27.68 27.42 35.74
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 8.08 11.41 9.32 11.58 15.92 16.42 19.53 15.09 22.56 25.64 37.62
Quick Ratio		 6.86 9.79 8.25 10.47 13.78 14.69 17.65 13.52 20.44 23.18 34.36
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 16 15 13 18 -5.91 17 20 22 18 12 10
Operating Cash Flow to CapEx		 7,841.48% 441.18% 1,058.74% 0.00% 3,158.52% 2,341.51% 3,841.12% 2,613.97% 3,486.85% 7,305.91% 3,960.11%
Free Cash Flow to Firm to Interest Expense		 241.53 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 212.32 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 209.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.50 0.51 0.49 0.44 0.45 0.38 0.43 0.44 0.39 0.32 0.31
Accounts Receivable Turnover		 8.67 10.11 12.12 11.08 10.79 9.54 10.62 9.80 11.25 10.93 10.12
Inventory Turnover		 3.52 3.57 3.07 2.95 2.83 2.53 2.83 2.61 2.19 1.82 1.97
Fixed Asset Turnover		 5.15 4.53 3.84 3.82 4.45 3.83 4.47 5.02 4.84 4.03 3.92
Accounts Payable Turnover		 20.24 20.07 16.33 16.44 16.82 17.64 23.42 20.30 20.32 22.88 20.56
Days Sales Outstanding (DSO)		 42.11 36.10 30.12 32.93 33.84 38.28 34.36 37.25 32.45 33.40 36.08
Days Inventory Outstanding (DIO)		 103.61 102.17 118.91 123.93 129.00 144.16 128.98 140.02 166.32 200.29 185.02
Days Payable Outstanding (DPO)		 18.03 18.18 22.36 22.20 21.70 20.70 15.59 17.98 17.96 15.95 17.75
Cash Conversion Cycle (CCC)		 127.69 120.09 126.67 134.66 141.15 161.73 147.75 159.29 180.80 217.74 203.35
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 46 43 38 38 58 52 46 40 36 35 34
Invested Capital Turnover		 0.83 0.88 1.02 1.10 0.98 0.77 1.00 1.22 1.33 1.16 1.13
Increase / (Decrease) in Invested Capital		 -3.78 -3.43 -4.72 -0.29 20 -6.74 -5.40 -6.62 -3.80 -1.01 -1.00
Enterprise Value (EV)		 169 218 234 233 329 237 291 277 200 125 93
Market Capitalization		 193 244 274 284 372 288 352 352 292 207 179
Book Value per Share		 $18.57 $18.41 $21.00 $23.83 $27.17 $28.24 $29.35 $31.50 $35.35 $34.62 $37.45
Tangible Book Value per Share		 $8.19 $9.97 $12.41 $16.20 $15.30 $17.76 $20.62 $24.95 $30.22 $29.77 $32.77
Total Capital		 70 69 78 89 101 103 107 115 129 118 119
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.34 0.30 0.28 0.23
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.34 0.00 0.34 0.30 0.28 0.23
Net Debt		 -23 -26 -40 -51 -43 -51 -61 -75 -93 -83 -86
Capital Expenditures (CapEx)		 0.18 3.29 1.60 -0.46 0.54 0.86 0.55 0.81 0.64 0.20 0.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 5.47 5.09 3.95 4.53 8.65 6.88 8.44 8.91 8.69 9.60 9.39
Debt-free Net Working Capital (DFNWC)		 29 31 44 56 51 58 69 84 102 93 95
Net Working Capital (NWC)		 29 31 44 56 51 58 69 84 102 93 95
Net Nonoperating Expense (NNE)		 0.08 -0.17 -0.03 -0.73 -0.21 -0.10 -0.14 -0.69 -2.74 -2.65 -2.17
Net Nonoperating Obligations (NNO)		 -23 -26 -40 -51 -43 -51 -61 -75 -93 -83 -86
Total Depreciation and Amortization (D&A)		 3.15 2.83 2.77 2.96 6.88 7.21 7.28 7.08 6.37 2.85 3.01
Debt-free, Cash-free Net Working Capital to Revenue		 13.63% 12.96% 9.55% 10.79% 18.44% 16.31% 17.20% 17.04% 17.30% 23.46% 24.37%
Debt-free Net Working Capital to Revenue		 71.74% 80.03% 106.02% 132.49% 109.67% 138.63% 141.50% 160.59% 202.21% 226.32% 247.00%
Net Working Capital to Revenue		 71.74% 80.03% 106.02% 132.49% 109.67% 138.63% 141.50% 160.59% 202.21% 226.32% 247.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $3.16 $3.23 $2.29 $4.97 $3.96 $2.95 $4.05 $0.00 $4.58 $3.96 $3.48
Adjusted Weighted Average Basic Shares Outstanding		 3.75M 3.72M 3.73M 3.72M 3.70M 3.65M 3.65M 0.00 3.59M 3.28M 3.19M
Adjusted Diluted Earnings per Share		 $3.14 $3.22 $2.28 $4.95 $3.94 $2.94 $4.04 $0.00 $4.57 $3.96 $3.48
Adjusted Weighted Average Diluted Shares Outstanding		 3.75M 3.72M 3.73M 3.72M 3.70M 3.65M 3.65M 0.00 3.59M 3.28M 3.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.75M 3.72M 3.73M 3.72M 3.70M 3.65M 3.65M 0.00 3.59M 3.28M 3.19M
Normalized Net Operating Profit after Tax (NOPAT)		 12 12 13 18 15 11 15 16 14 11 9.12
Normalized NOPAT Margin		 29.69% 30.42% 32.13% 42.45% 30.96% 25.36% 29.86% 30.18% 27.66% 27.44% 23.68%
Pre Tax Income Margin		 38.71% 41.79% 46.08% 46.33% 38.13% 32.81% 38.86% 39.52% 40.00% 41.08% 36.63%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 238.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 183.44 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 235.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 180.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 32.47% 32.29% 34.74% 21.70% 27.92% 38.12% 77.53% 19.20% 25.74% 30.70% 35.29%
Augmented Payout Ratio		 32.47% 32.29% 34.74% 28.19% 30.62% 102.72% 77.53% 34.35% 25.74% 174.63% 109.32%

Quarterly Metrics And Ratios for Utah Medical Products

This table displays calculated financial ratios and metrics derived from Utah Medical Products' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 3/31/2026
DEI Shares Outstanding		 3,629,525.00 3,629,525.00 3,589,014.00 3,528,426.00 3,477,117.00 - 3,281,816.00 3,248,210.00 3,185,025.00
DEI Adjusted Shares Outstanding		 3,629,525.00 3,629,525.00 3,589,014.00 3,528,426.00 3,477,117.00 - 3,281,816.00 3,248,210.00 3,185,025.00
DEI Earnings Per Adjusted Shares Outstanding		 0.81 1.55 0.93 0.97 1.44 - 1.15 1.50 0.66
Growth Metrics		 - - - - - - - - -
Revenue Growth		 -3.47% -9.15% -9.42% -19.17% -19.99% -25.74% -14.37% -4.30% -10.18%
EBITDA Growth		 -7.31% -54.95% -20.37% -29.45% -25.08% -67.94% -16.46% -6.32% -15.48%
EBIT Growth		 -10.45% -60.06% -6.27% -18.58% -12.59% -88.17% -19.59% -8.91% -17.52%
NOPAT Growth		 -20.74% -18.45% -12.39% -21.55% -12.75% -30.17% -22.37% -9.92% -15.54%
Net Income Growth		 -8.06% -5.93% -6.12% -17.79% -9.45% -32.29% -23.13% -11.73% -14.37%
EPS Growth		 -8.47% -6.35% -6.03% -14.78% -5.56% -26.27% -15.60% -4.08% -10.87%
Operating Cash Flow Growth		 -8.37% -6.13% -23.70% -43.78% -24.70% -44.92% -15.39% 4.02% -30.35%
Free Cash Flow Firm Growth		 -39.56% -33.30% -40.46% -33.33% -59.92% -53.16% -55.44% -55.62% 7.36%
Invested Capital Growth		 -8.28% -9.62% -7.78% -6.27% 0.69% -2.82% -0.67% 0.70% -2.39%
Revenue Q/Q Growth		 -2.81% -1.38% -8.05% -8.29% -3.80% -8.47% 6.03% 2.50% 0.00%
EBITDA Q/Q Growth		 -5.54% -54.29% 82.64% -10.53% 0.31% -80.44% 375.99% 0.33% 0.00%
EBIT Q/Q Growth		 -7.56% -58.98% 144.67% -12.23% -0.76% -94.45% 1,562.93% -0.57% 0.00%
NOPAT Q/Q Growth		 -9.09% 3.14% -4.98% -11.95% 1.10% -17.45% 5.63% 2.18% 0.00%
Net Income Q/Q Growth		 -6.31% 8.92% -7.70% -12.71% 3.19% -18.55% 4.79% 0.23% 0.00%
EPS Q/Q Growth		 -6.09% 9.26% -7.63% -10.09% 4.08% -14.71% 5.75% 2.17% 0.00%
Operating Cash Flow Q/Q Growth		 4.23% 4.12% -1.05% -47.65% 39.61% -23.83% 51.99% -35.64% 0.00%
Free Cash Flow Firm Q/Q Growth		 -16.17% 10.38% -15.11% -15.12% -49.61% 29.01% -19.24% -15.47% 0.00%
Invested Capital Q/Q Growth		 -4.43% -0.16% -4.26% 2.60% 2.67% -3.64% -2.14% 4.01% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 58.85% 57.54% 59.66% 60.13% 57.99% 58.11% 57.03% 56.21% 60.56%
EBITDA Margin		 52.51% 24.33% 48.33% 47.15% 49.17% 10.50% 47.16% 46.16% 44.37%
Operating Margin		 31.74% 31.98% 34.24% 33.06% 33.41% 31.99% 32.47% 32.11% 29.41%
EBIT Margin		 38.23% 15.90% 42.31% 40.49% 41.77% 2.53% 39.73% 38.54% 36.48%
Profit (Net Income) Margin		 31.47% 34.75% 34.89% 33.20% 35.61% 31.69% 31.32% 30.62% 29.86%
Tax Burden Percent		 82.31% 85.43% 82.45% 82.00% 85.26% 80.30% 78.82% 79.46% 81.84%
Interest Burden Percent		 100.00% 255.84% 100.00% 100.00% 100.00% 1,557.76% 100.00% 100.00% 100.00%
Effective Tax Rate		 17.70% 14.57% 17.55% 18.00% 14.74% 19.70% 21.18% 20.54% 18.16%
Return on Invested Capital (ROIC)		 35.93% 36.45% 38.83% 34.80% 34.96% 29.82% 29.47% 28.12% 26.90%
ROIC Less NNEP Spread (ROIC-NNEP)		 35.08% 35.36% 37.96% 34.07% 34.15% 29.20% 28.84% 27.52% 26.30%
Return on Net Nonoperating Assets (RNNOA)		 -23.76% -24.38% -26.94% -24.01% -24.25% -20.82% -20.81% -19.50% -18.86%
Return on Equity (ROE)		 12.17% 12.07% 11.88% 10.79% 10.71% 9.00% 8.67% 8.62% 8.03%
Cash Return on Invested Capital (CROIC)		 47.78% 47.01% 45.78% 41.37% 33.40% 34.71% 31.48% 28.34% 28.43%
Operating Return on Assets (OROA)		 15.76% 6.16% 15.77% 14.48% 14.11% 0.80% 12.10% 11.93% 11.09%
Return on Assets (ROA)		 12.97% 13.46% 13.00% 11.87% 12.03% 10.05% 9.54% 9.48% 9.08%
Return on Common Equity (ROCE)		 12.17% 12.07% 11.88% 10.79% 10.71% 9.00% 8.67% 8.62% 8.03%
Return on Equity Simple (ROE_SIMPLE)		 13.67% 0.00% 12.82% 0.00% 12.29% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 3.27 3.37 3.20 2.82 2.85 2.35 2.49 2.54 2.10
NOPAT Margin		 26.12% 27.32% 28.23% 27.11% 28.49% 25.69% 25.60% 25.51% 24.07%
Net Nonoperating Expense Percent (NNEP)		 0.85% 1.10% 0.87% 0.73% 0.81% 0.63% 0.63% 0.59% 0.59%
Return On Investment Capital (ROIC_SIMPLE)		 - 2.62% 2.50% 2.27% - 2.00% 2.12% 2.16% 1.74%
Cost of Revenue to Revenue		 41.15% 42.46% 40.34% 39.88% 42.01% 41.89% 42.97% 43.79% 39.44%
SG&A Expenses to Revenue		 26.01% 10.73% 23.08% 24.62% 22.86% 4.05% 22.98% 22.75% 29.39%
R&D to Revenue		 1.10% 1.18% 2.35% 2.45% 1.72% 1.31% 1.59% 1.36% 1.77%
Operating Expenses to Revenue		 27.11% 25.57% 25.42% 27.07% 24.58% 26.12% 24.56% 24.10% 31.15%
Earnings before Interest and Taxes (EBIT)		 4.78 1.96 4.80 4.21 4.18 0.23 3.86 3.84 3.18
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 6.57 3.00 5.48 4.90 4.92 0.96 4.58 4.59 3.87
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 2.48 2.28 1.96 1.86 1.87 1.77 1.54 1.57 1.64
Price to Tangible Book Value (P/TBV)		 2.93 2.67 2.28 2.17 2.18 2.05 1.79 1.82 1.86
Price to Revenue (P/Rev)		 5.96 5.82 5.11 4.96 5.28 5.07 4.59 4.76 5.26
Price to Earnings (P/E)		 15.88 16.24 15.10 15.11 13.40 16.43 13.79 12.74 16.29
Dividend Yield		 1.40% 1.47% 1.71% 1.83% 1.79% 1.97% 2.20% 2.13% 1.98%
Earnings Yield		 6.30% 6.16% 6.62% 6.62% 7.46% 6.09% 7.25% 7.85% 6.14%
Enterprise Value to Invested Capital (EV/IC)		 6.12 5.59 4.58 4.05 4.01 3.59 2.86 2.91 3.32
Enterprise Value to Revenue (EV/Rev)		 4.26 3.98 3.20 3.05 3.28 3.05 2.47 2.65 2.94
Enterprise Value to EBITDA (EV/EBITDA)		 8.10 8.54 7.13 7.12 7.89 7.66 6.32 6.82 8.12
Enterprise Value to EBIT (EV/EBIT)		 10.96 11.74 9.39 9.02 9.54 9.29 7.78 8.48 10.39
Enterprise Value to NOPAT (EV/NOPAT)		 14.96 14.39 11.67 11.22 11.80 11.11 9.24 10.04 12.62
Enterprise Value to Operating Cash Flow (EV/OCF)		 9.68 8.97 7.60 7.68 8.39 8.41 6.93 7.27 8.27
Enterprise Value to Free Cash Flow (EV/FCFF)		 12.25 11.30 9.61 9.47 12.04 10.19 9.04 10.29 11.55
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.68 -0.69 -0.71 -0.70 -0.71 -0.71 -0.72 -0.71 -0.72
Leverage Ratio		 1.08 1.07 1.07 1.06 1.05 1.05 1.05 1.04 1.04
Compound Leverage Factor		 1.08 2.74 1.07 1.06 1.05 16.35 1.05 1.04 1.04
Debt to Total Capital		 0.25% 0.23% 0.22% 0.22% 0.24% 0.24% 0.23% 0.00% 0.17%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.25% 0.23% 0.22% 0.22% 0.24% 0.24% 0.23% 0.00% 0.17%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.75% 99.77% 99.78% 99.78% 99.76% 99.76% 99.77% 100.00% 99.83%
Debt to EBITDA		 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.02
Net Debt to EBITDA		 -3.25 -3.96 -4.25 -4.46 -4.82 -5.08 -5.41 0.00 -6.42
Long-Term Debt to EBITDA		 0.01 0.01 0.01 0.01 0.02 0.02 0.02 0.00 0.02
Debt to NOPAT		 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.00 0.02
Net Debt to NOPAT		 -6.00 -6.66 -6.96 -7.03 -7.20 -7.37 -7.90 0.00 -9.98
Long-Term Debt to NOPAT		 0.02 0.02 0.02 0.02 0.02 0.03 0.03 0.00 0.02
Altman Z-Score		 27.27 27.31 22.33 26.01 28.20 27.07 22.54 36.75 32.34
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 24.38 22.56 19.57 25.98 29.59 25.64 22.29 41.87 28.64
Quick Ratio		 21.95 20.44 17.79 23.58 26.83 23.18 20.18 38.07 25.97
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 6.50 7.17 6.09 5.17 2.60 3.36 2.71 2.29 2.91
Operating Cash Flow to CapEx		 2,753.23% 5,924.44% 0.00% 2,510.91% 4,332.58% 32,633.33% 2,426.09% 5,633.33% 2,391.54%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.41 0.39 0.37 0.36 0.34 0.32 0.30 0.31 0.30
Accounts Receivable Turnover		 10.81 11.25 13.24 12.81 12.23 10.93 10.42 10.64 9.90
Inventory Turnover		 2.24 2.19 2.09 1.99 1.93 1.82 1.83 1.92 1.82
Fixed Asset Turnover		 5.10 4.84 4.78 4.49 4.25 4.03 3.89 3.80 3.82
Accounts Payable Turnover		 22.44 20.32 19.83 17.61 24.05 22.88 17.11 21.09 14.98
Days Sales Outstanding (DSO)		 33.76 32.45 27.57 28.49 29.84 33.40 35.01 34.31 36.86
Days Inventory Outstanding (DIO)		 162.80 166.32 174.29 183.19 189.09 200.29 199.57 190.45 200.80
Days Payable Outstanding (DPO)		 16.26 17.96 18.41 20.73 15.17 15.95 21.33 17.30 24.37
Cash Conversion Cycle (CCC)		 180.30 180.80 183.45 190.95 203.76 217.74 213.25 207.46 213.29
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 36 36 34 35 36 35 34 35 33
Invested Capital Turnover		 1.38 1.33 1.38 1.28 1.23 1.16 1.15 1.10 1.12
Increase / (Decrease) in Invested Capital		 -3.23 -3.80 -2.89 -2.35 0.25 -1.01 -0.23 0.25 -0.81
Enterprise Value (EV)		 219 200 157 142 145 125 97 103 110
Market Capitalization		 307 292 250 231 233 207 180 185 197
Book Value per Share		 $34.08 $35.35 $35.59 $35.16 $35.72 $34.62 $35.67 $36.18 $37.79
Tangible Book Value per Share		 $28.83 $30.22 $30.57 $30.19 $30.65 $29.77 $30.74 $31.21 $33.31
Total Capital		 124 129 128 124 124 118 117 118 121
Total Debt		 0.31 0.30 0.29 0.28 0.30 0.28 0.27 0.00 0.21
Total Long-Term Debt		 0.31 0.30 0.29 0.28 0.30 0.28 0.27 0.00 0.21
Net Debt		 -88 -93 -94 -89 -88 -83 -83 -82 -87
Capital Expenditures (CapEx)		 0.19 0.09 -0.01 0.11 0.09 0.01 0.18 0.05 0.13
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 9.46 8.69 7.87 9.16 9.77 9.60 8.75 9.94 9.47
Debt-free Net Working Capital (DFNWC)		 98 102 102 98 98 93 92 92 97
Net Working Capital (NWC)		 98 102 102 98 98 93 92 92 97
Net Nonoperating Expense (NNE)		 -0.67 -0.92 -0.75 -0.63 -0.71 -0.55 -0.56 -0.51 -0.50
Net Nonoperating Obligations (NNO)		 -88 -93 -94 -89 -88 -83 -83 -82 -87
Total Depreciation and Amortization (D&A)		 1.79 1.04 0.68 0.69 0.74 0.73 0.72 0.76 0.69
Debt-free, Cash-free Net Working Capital to Revenue		 18.38% 17.30% 16.04% 19.67% 22.16% 23.46% 22.28% 25.61% 25.22%
Debt-free Net Working Capital to Revenue		 189.78% 202.21% 207.31% 211.22% 222.83% 226.32% 234.45% 237.27% 258.11%
Net Working Capital to Revenue		 189.78% 202.21% 207.31% 211.22% 222.83% 226.32% 234.45% 237.27% 258.11%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.08 $1.18 $1.09 $0.98 $1.02 $0.87 $0.92 $0.94 $0.82
Adjusted Weighted Average Basic Shares Outstanding		 3.63M 3.59M 3.62M 3.53M 3.48M 3.28M 3.31M 3.25M 3.19M
Adjusted Diluted Earnings per Share		 $1.08 $1.18 $1.09 $0.98 $1.02 $0.87 $0.92 $0.94 $0.82
Adjusted Weighted Average Diluted Shares Outstanding		 3.64M 3.59M 3.62M 3.53M 3.48M 3.28M 3.31M 3.25M 3.19M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 3.63M 3.59M 3.53M 3.48M 3.39M 3.28M 3.25M 3.21M 3.18M
Normalized Net Operating Profit after Tax (NOPAT)		 3.27 3.37 3.20 2.82 2.85 2.35 2.49 2.54 2.10
Normalized NOPAT Margin		 26.12% 27.32% 28.23% 27.11% 28.49% 25.69% 25.60% 25.51% 24.07%
Pre Tax Income Margin		 38.23% 40.68% 42.31% 40.49% 41.77% 39.46% 39.73% 38.54% 36.48%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 25.21% 25.74% 26.26% 27.59% 28.14% 30.70% 32.32% 32.72% 36.46%
Augmented Payout Ratio		 25.21% 25.74% 44.52% 87.68% 115.03% 174.63% 188.19% 170.39% 84.96%

Financials Breakdown Chart

Key Financial Trends

Utah Medical Products (NASDAQ: UTMD) started fiscal 2026 with a stronger balance sheet and solid profitability, but revenue growth remains the main challenge. The company continues to generate healthy operating cash flow, carries little debt, and has a large net cash position. At the same time, quarterly sales are below prior-year levels, and buybacks plus dividends remain a meaningful use of cash.

  • UTMD ended Q1 2026 with $87.4 million in cash and equivalents and only $4.0 million in total liabilities, giving it an exceptionally strong liquidity profile.
  • The company produced $3.1 million in operating cash flow in Q1 2026, which is strong relative to its size and supports ongoing capital returns.
  • Free cash flow appears healthy: UTMD spent only $130,000 on capex in Q1 2026, leaving substantial cash generation after investment needs.
  • UTMD continues to report solid profitability, with $2.6 million in net income in Q1 2026 and $0.82 EPS.
  • Debt is minimal, with just $210,000 of long-term debt on the balance sheet at the end of Q1 2026.
  • Retained earnings remain very high at $130.3 million, reflecting a long record of accumulated profitability.
  • The company’s current ratio is very strong, with $100.4 million in current assets versus $3.5 million in current liabilities.
  • Cash declined only modestly from $82.2 million in Q2 2025 to $87.4 million in Q1 2026, after factoring in operating activity, buybacks, dividends, and other cash items.
  • Intangible assets and goodwill remain meaningful parts of the asset base, but they are well supported by the company’s low leverage and large cash reserve.
  • Q1 2026 revenue fell to $8.7 million from $9.7 million in Q1 2025, showing a year-over-year sales decline.
  • Gross profit also slipped year over year, with $5.28 million in Q1 2026 versus $5.54 million in Q1 2025.
  • Operating income dropped to $2.57 million from $3.15 million a year ago, indicating some pressure on core operating performance.
  • The company returned a lot of cash to shareholders, including $989,000 in dividends and $128,000 in share repurchases in Q1 2026, which reduced cash even as earnings remained positive.
  • Compared with the stronger year-ago quarter, Q1 2026 net income attributable to common shareholders fell to $2.1 million from $3.8 million, largely due to lower non-operating/adjustment items.

Looking at the broader multi-year trend, UTMD has remained consistently profitable and cash-generative, but quarterly revenue has been uneven and has softened versus 2024 levels. The main bullish takeaway is the company’s balance sheet: UTMD has more cash than total liabilities, very limited debt, and enough operating cash flow to keep funding dividends and buybacks. The main risk is that revenue and operating income have not shown sustained growth, so future share performance will likely depend on whether management can stabilize sales while preserving margins.

07/05/26 12:03 AM ETAI Generated. May Contain Errors.

Utah Medical Products Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Utah Medical Products' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

The last 5 years of Utah Medical Products' net income performance:
  • 2021: $14.79 million
  • 2022: $16.47 million
  • 2023: $16.64 million
  • 2024: $13.87 million
  • 2025: $11.29 million
Find out what analysts predict for Utah Medical Products in the coming months.

Utah Medical Products' total operating income in 2025 was $11.40 million, based on the following breakdown:
  • Total Gross Profit: $22.00 million
  • Total Operating Expenses: $10.60 million

Over the last 10 years, Utah Medical Products' total revenue changed from $40.16 million in 2015 to $38.52 million in 2025, a change of -4.1%.

Utah Medical Products' total liabilities were at $3.27 million at the end of 2025, a 35.9% decrease from 2024, and a 65.6% decrease since 2015.

In the past 10 years, Utah Medical Products' cash and equivalents has ranged from $23.28 million in 2015 to $92.87 million in 2023, and is currently $85.76 million as of their latest financial filing in 2025.

Over the last 10 years, Utah Medical Products' book value per share changed from 18.57 in 2015 to 37.45 in 2025, a change of 101.6%.


Related Companies

Financial statements for NASDAQ:UTMD last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
**MARKET CRASH WARNING**
A former advisor to the Pentagon and CIA is warning that an 80% Dow drop could arrive within days - and names ...
Paradigm Press | Sponsoredtc pixel
Two Legends Issue Rare Buy Alert on Elon Musk Supplier
Jeff Brown and Marc Chaikin - the two investors who picked Nvidia before it climbed as much as 36,000% - are i...
Brownstone Research | Sponsoredtc pixel
He turned $12,415 into millions. Now he wants to help you.
Tim Sykes turned $12,415 in bar mitzvah money into over $7 million in trading profits - and more than 50 of hi...
Tim Sykes | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
Urgent exposé on the "Mar-a-Lago Trade"
Dr. David Eifrig, former Goldman Sachs VP and Senior Partner at Stansberry Research, has released an urgent ex...
Stansberry Research | Sponsoredtc pixel
The REAL Reason Trump is Invading Iran
For a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...
Banyan Hill Publishing | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The pre-flight check for options traders
Pilots never skip their pre-flight checklist - and neither should options traders. The Smart Trade Options Che...
Profits Run | Sponsoredtc pixel